Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5.
Gut. 2019.
PMID: 29730603